Denali sells Rare Pediatric Disease PRV for $195M to fund pipeline

Denali Therapeutics Inc.

Gross proceeds of $195M from sale of PRV awarded after FDA approval of AVLAYAH for Hunter syndrome in March 2026.
Proceeds to advance clinical pipeline including DNL126 (MPS IIIA), DNL593 (FTD), DNL952 (Pompe), DNL628 (Alzheimer's).
Transaction subject to HSR waiting period; expected to close after customary conditions.
Denali's TV platform enabled AVLAYAH, first FDA-approved biologic to cross blood-brain barrier via transferrin receptor.

item 1.01 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #10 for 2026-06-18. Read digest

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Denali Therapeutics Inc. entered into PRV Transfer Agreement valued at $195 million (effective 2026-06-12).

Action: entry
Agreement: asset purchase
Value: $195 million
Effective: 2026-06-12

Exact text from the filing

On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”).

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-26-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.